Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Immunome logo
ImmunomeIMNM
$0-100%
Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Allogene Therapeutics (ALLO) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $72.12M in Q1 2026.
How has Allogene Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
Allogene Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale increased by 27.6% year-over-year, from $56.5M to $72.12M.
What is the long-term trend for Allogene Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Over 4 years (2021 to 2025), Allogene Therapeutics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a -24.7% compound annual growth rate (CAGR), from $728.39M to $234.2M.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.